These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32768729)

  • 41. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
    Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
    Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Salicylaldehyde-derived piperazine-functionalized hydrazone ligand-based Pt(II) complexes: inhibition of EZH2-dependent tumorigenesis in pancreatic ductal adenocarcinoma, synergism with PARP inhibitors and enhanced apoptosis.
    Lv Z; Ali A; Zou C; Wang Z; Ma M; Cheng N; Shad M; Hao H; Zhang Y; Rahman FU
    Dalton Trans; 2024 Aug; 53(33):13871-13889. PubMed ID: 39091221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium(II) β-carboline complexes.
    Chen J; Peng F; Zhang Y; Li B; She J; Jie X; Zou Z; Chen M; Chen L
    Eur J Med Chem; 2017 Nov; 140():104-117. PubMed ID: 28923379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anticancer and antibacterial potential of robust Ruthenium(II) arene complexes regulated by choice of α-diimine and halide ligands.
    Zanda E; Busto N; Biancalana L; Zacchini S; Biver T; Garcia B; Marchetti F
    Chem Biol Interact; 2021 Aug; 344():109522. PubMed ID: 34029541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Highly Cytotoxic Ruthenium(II)-Arene Complexes from Bulky 1-Pyrenylphosphane Ligands.
    Brissos RF; Clavero P; Gallen A; Grabulosa A; Barrios LA; Caballero AB; Korrodi-Gregório L; Pérez-Tomás R; Muller G; Soto-Cerrato V; Gamez P
    Inorg Chem; 2018 Dec; 57(23):14786-14797. PubMed ID: 30444630
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
    Yuan Z; Chen S; Chen C; Chen J; Chen C; Dai Q; Gao C; Jiang Y
    Eur J Med Chem; 2017 Sep; 138():1135-1146. PubMed ID: 28763648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ru
    Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
    Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model.
    Miachin K; Del Solar V; El Khoury E; Nayeem N; Khrystenko A; Appelt P; Neary MC; Buccella D; Contel M
    Inorg Chem; 2021 Dec; 60(24):19152-19164. PubMed ID: 34846878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Triazole-Based Half-Sandwich Ruthenium(II) Compounds: From
    Lenis-Rojas OA; Cabral R; Carvalho B; Friães S; Roma-Rodrigues C; Fernández JAA; Vila SF; Sanchez L; Gomes CSB; Fernandes AR; Royo B
    Inorg Chem; 2021 Jun; 60(11):8011-8026. PubMed ID: 33973771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands.
    Łomzik M; Hanif M; Budniok A; Błauż A; Makal A; Tchoń DM; Leśniewska B; Tong KKH; Movassaghi S; Söhnel T; Jamieson SMF; Zafar A; Reynisson J; Rychlik B; Hartinger CG; Plażuk D
    Inorg Chem; 2020 Oct; 59(20):14879-14890. PubMed ID: 33003697
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and characterization of polypyridine ruthenium(II) complexes and anticancer efficacy studies in vivo and in vitro.
    Liang L; Wu X; Shi C; Wen H; Wu S; Chen J; Huang C; Wang Y; Liu Y
    J Inorg Biochem; 2022 Nov; 236():111963. PubMed ID: 35988387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lin C; Liu C; Hu P; Zou Z; Sun G
    Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Similarities and differences in d
    Gilewska A; Barszcz B; Masternak J; Kazimierczuk K; Sitkowski J; Wietrzyk J; Turlej E
    J Biol Inorg Chem; 2019 Jun; 24(4):591-606. PubMed ID: 31115765
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
    Yu J; Luo L; Hu T; Cui Y; Sun X; Gou W; Hou W; Li Y; Sun T
    Eur J Med Chem; 2022 Jan; 227():113898. PubMed ID: 34656898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy.
    Yusoh NA; Ahmad H; Gill MR
    ChemMedChem; 2020 Nov; 15(22):2121-2135. PubMed ID: 32812709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring the Molecular Mechanisms Underlying the in vitro Anticancer Effects of Multitarget-Directed Hydrazone Ruthenium(II)-Arene Complexes.
    Cuccioloni M; Bonfili L; Cecarini V; Nabissi M; Pettinari R; Marchetti F; Petrelli R; Cappellacci L; Angeletti M; Eleuteri AM
    ChemMedChem; 2020 Jan; 15(1):105-113. PubMed ID: 31701643
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "Half-Sandwich" Ruthenium Complexes with Alizarin as Anticancer Agents:
    de Araujo-Neto JH; Guedes APM; Leite CM; Moraes CAF; Santos AL; Brito RDS; Rocha TL; Mello-Andrade F; Ellena J; Batista AA
    Inorg Chem; 2023 May; 62(18):6955-6969. PubMed ID: 37099760
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, Characterization, Cytotoxic Activity, and Metabolic Studies of Ruthenium(II) Polypyridyl Complexes Containing Flavonoid Ligands.
    Munteanu AC; Notaro A; Jakubaszek M; Cowell J; Tharaud M; Goud B; Uivarosi V; Gasser G
    Inorg Chem; 2020 Apr; 59(7):4424-4434. PubMed ID: 32191449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
    Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
    J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.